carbidopa/levodopa intranasal (INP107)
/ Impel Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
December 13, 2018
THOR 201: Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
(clinicaltrials.gov)
- P2a | N=24 | Recruiting | Sponsor: Impel NeuroPharma Inc. | Trial completion date: Nov 2018 ➔ Jul 2019 | Trial primary completion date: Sep 2018 ➔ Jun 2019
Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Myelodysplastic Syndrome • Parkinson's Disease • COMT
June 03, 2018
THOR 201: Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
(clinicaltrials.gov)
- P2a | N=24 | Recruiting | Sponsor: Impel NeuroPharma Inc.
New P2a trial • Movement Disorders • Myelodysplastic Syndrome • Parkinson's Disease • COMT
March 19, 2019
THOR 201: Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
(clinicaltrials.gov)
- P2a | N=32 | Recruiting | Sponsor: Impel NeuroPharma Inc. | N=24 ➔ 32
Enrollment change • CNS Disorders • Movement Disorders • Myelodysplastic Syndrome • Parkinson's Disease • COMT
June 18, 2019
THOR 201: Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
(clinicaltrials.gov)
- P2a | N=32 | Completed | Sponsor: Impel NeuroPharma Inc. | Recruiting ➔ Completed
Trial completion • CNS Disorders • Movement Disorders • Myelodysplastic Syndrome • Parkinson's Disease • COMT
1 to 4
Of
4
Go to page
1